Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course Source: Eur Respir J , 49 (3) 1600537; DOI: 10.1183/13993003.00537-2016 Year: 2017
The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017
Insufficient serum L-ficolin is associated with the disease progression in pulmonary Mycobacterium avium complex disease Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
The second recurrence of Mycobacterium avium complex lung disease after successful treatment for first recurrence Source: Eur Respir J, 53 (1) 1801038; 10.1183/13993003.01038-2018 Year: 2019
Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection Source: Eur Respir J 2015; 46: 1823-1826 Year: 2015
Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Clinical characteristics and outcomes of patients with Mycobacterium avium complex lung disease positive for Aspergillus precipitating antibody Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Mycobacterium avium complex infection: phenotypes and outcomesSource: Eur Respir J, 50 (3) 1701380; 10.1183/13993003.01380-2017 Year: 2017
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Susceptibility to nontuberculous mycobacterial lung disease Source: Eur Respir J 2008; 31: 1322-1333 Year: 2008
Risk factors for Mycobacterium tuberculosis infection among contacts of pulmonary tuberculosis patients Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012
Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003